STOCK TITAN

Citius Pharmaceuticals (CTXR) Stock News, Feb-May 2024

CTXR NASDAQ

Citius Pharmaceuticals reports developments across its critical care and targeted oncology business, including activity at majority-owned subsidiary Citius Oncology. The company’s recurring updates center on LYMPHIR (denileukin diftitox-cxdl), an engineered IL-2 diphtheria toxin fusion protein approved for adults with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.

Company news also covers LYMPHIR commercialization, U.S. launch progress, international access through Named Patient Programs, and investigator-initiated oncology studies involving gynecologic cancers and diffuse large B-cell lymphoma. Capital updates include registered direct offerings, warrant issuances, non-dilutive funding and other financing actions that support product commercialization and development programs.

Rhea-AI Summary

Citius Pharmaceuticals (CTXR) reported its fiscal Q2 2024 financial results and provided a business update. Key highlights include:

- The FDA accepted LYMPHIR's BLA with a PDUFA target date of Aug 13, 2024.

- Topline results for Mino-Lok’s Phase 3 trial expected in Q2 2024.

- Continued engagement with FDA for Halo-Lido’s development.

- Merger with TenX Keane Acquisition progressing, awaiting SEC and TENK shareholder approval.

- Completed a $15M direct offering in April 2024, extending cash runway to Dec 2024.

Financial highlights:

- $12.6M in cash as of Mar 31, 2024.

- R&D expenses decreased to $3.6M from $4.7M YoY; G&A expenses slightly decreased to $4.3M from $4.8M YoY.

- Net loss improved to $8.5M, $0.05 per share, from $10.5M, $0.07 per share YoY.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.15%
Tags
-
Rhea-AI Summary

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) will participate in the upcoming EF Hutton and H.C. Wainwright investor conferences. CEO Leonard Mazur will host one-on-one investor meetings at the EF Hutton Annual Global Conference on May 15, 2024, and present at the H.C. Wainwright BioConnect Investor Conference on May 20, 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.91%
Tags
conferences
-
Rhea-AI Summary

Citius Pharmaceuticals Inc. (Nasdaq: CTXR) closed a registered direct offering, raising $15 million through the sale of 21,428,574 shares and warrants. The offering was facilitated by H.C. Wainwright & Co. The company plans to utilize the funds for general corporate purposes, including product development and working capital.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.68%
Tags
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.25%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.00%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.34%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.50%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.80%
Tags
conferences

FAQ

What is the current stock price of Citius Pharmaceuticals (CTXR)?

Citius Pharmaceuticals (CTXR) last closed at $0.5107.

What is the market cap of Citius Pharmaceuticals (CTXR)?

The market cap of Citius Pharmaceuticals (CTXR) is approximately $14.0M.